11:22 AM EDT, 04/29/2025 (MT Newswires) -- Danaher's ( DHR ) Aldevron unit and Kytopen said Tuesday they have signed a joint marketing agreement to promote the combination of the Aldveron Nanoplasmid vector technology with Kytopen's Flowfect Tx GMP cellular engineering platform.

The companies said the combination is intended to accelerate cell therapy manufacturing by improving manufacturers' CRISPR-mediated T-cell engineering workflow.

Price: 197.62, Change: +1.71, Percent Change: +0.87